Navigation Links
New FASEB analysis documents impact of budget cuts on biomedical research
Date:5/17/2013

Bethesda, MD The Federation of American Societies for Experimental Biology (FASEB) released a new analysis of National Institutes of Health (NIH) funding trends highlighting the devastating impact of sequestration on the nation's capacity to support critical research. The FASEB analysis follows a May 15th Senate Appropriations Committee hearing featuring NIH Director, Francis Collins, MD, PhD, who testified that the $1.6 billion cut the agency sustained in FY 2013 due to sequestration is "having a substantial impact on the scientific community."

According to data from the NIH Website compiled by FASEB:

  • In constant dollars (adjusted for inflation), the NIH budget in FY 2013 is at its lowest level since FY 2000.

  • NIH awards are expected to drop from the 9,032 made in FY 2012 to an estimated 8,283 in FY 2013 (an 8.3 percent decrease).

A bipartisan group of senators joined Appropriations Committee Chair Barbara Mikulski (D-MD), Labor, Health and Human Services Subcommittee Chair Tom Harkin (D-IA) and subcommittee ranking member Jerry Moran (R-KS) in pledging to work together to do everything possible to increase the NIH budget in FY 2014.

FASEB urges Congress to restore the cuts and sustain the federal investment in NIH with a FY 2014 appropriation of at least $32 billion.


'/>"/>

Contact: Lawrence Green
lgreen@faseb.org
301-634-7335
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1

Related biology news :

1. FASEB 2013 Excellence in Science Award recipient announced
2. Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program
3. FASEB lauds Air India for transporting research animals
4. FASEB urges biomedical research community to speak out against sequestration
5. FASEB SRC announces conference: Gastrointestinal Tract XV: Epithelia, Microbes, Inflammation & Cancer
6. FASEB SRC announces conference registration open: The Biology of Calpains in Health and Disease
7. FASEB SRC announces: Mechanism and Regulation of Prokaryotic Transcription Conference
8. FASEB SRC announces conference: Renal Hemodynamics: Integrating with the Nephron & Beyond
9. FASEB SRC announces conference registration open for: Ciliate Molecular Biology
10. FASEB SRC announces conference registration open for: Mechanisms in Plant Development Conference
11. FASEB SRC announces conference registration open for: Hematologic Malignancies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... the University of California, Riverside have unlocked the molecular ... such as leaves to develop in a jigsaw-like pattern, ... findings were published in today's edition of the journal ... biology at the UCR's Center for Plant Cell Biology ...
... Northwestern University Feinberg School of Medicine played a ... of Abraxane (paclitaxel protein-bound particles for injectable suspension), ... "The approval means that women with metastatic breast ... associated with solvents and will no longer need ...
... that human leprosy infections provide for study of human ... warning system prompts a rapid immune response by two ... why, when threatened by microbes like the leprosy bug, ... but in other cases yields to a dangerous, spreading ...
Cached Biology News:Nanoparticle Breast Cancer Drug Approved by FDA 2Leprosy microbes lead scientists to immune discovery 2
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/17/2014)... Dec. 17, 2014   Synageva BioPharma Corp. ... therapeutic products for rare disorders, announced today its presentation ... in San Francisco, CA. ... Executive Officer, will present on Monday, January 12, 2015, ... will be webcast live and may be accessed from ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of ... that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded ... Israel,s Office of the Chief Scientist (OCS).  ... in receipt of grant support from the Office of ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... TEL-AVIV, Israel and PORTLAND, Oregon, October 2 , ... Exertion Identified,Abnormalities of Cardiovascular Function and Might be Useful ... Treatment in,Clinical Practice and Trials , ... Exercise Cardiac,Output (ECO(R)) stress test protocol for chronic heart ...
... --Company to Host Conference Call-- , CALGARY, Oct. 2 ... announced that it has reached an agreement with the ... Protocol Assessment (SPA) process for the design of a ... and carboplatin in patients with platinum-refractory head and neck ...
... ... Situational Leadership V™ series to its portfolio. , ... San Francisco, Calif. (PRWEB) October 2, 2009 -- ... series specifically for biotech and specialty pharma companies. The new series includes Situational Leadership ...
Cached Biology Technology:New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical's BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure 2New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical's BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Perceptum Group Announces New Situational Leadership V Series 2
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2...
HSPBP1 Antibody...
... CRE-bla HEK 293T cell line contains the ... cAMP response element (CRE). To obtain the ... into HEK 293T cells by lentivirus. Subsequent ... responsive to forskolin stimulation (Figure 1). The ...
Biology Products: